Skip to content
    Font Size

    New Drug Fights Advanced Prostate Cancer

    Cabazitaxel Extends Lives of Men With No More Treatment Options
    WebMD Health News
    Reviewed by Louise Chang, MD

    March 3, 2010 -- A new drug shows promise for extending the lives of men with advanced prostate cancer who have run out of treatment options.

    In a large study, men given the experimental drug, called cabazitaxel, lived an average of just over 15 months, while those given standard chemotherapy lived an average of nearly 13 months.

    Living an extra two or three months might not sound like much, but all the men had prostate cancer that had spread throughout the body despite standard treatment, says study head Oliver Sartor, MD, a cancer researcher at Tulane Cancer Center in New Orleans.

    "These men really don't have other alternatives," Sartor tells WebMD."They are only expected to live about a year. Cabazitaxel more than doubled the number of men that lived for at least two years."

    As many as 20,000 men in the U.S. could benefit from the drug each year, he says.

    Men with earlier prostate cancer might benefit even more, says American Society of Clinical Oncology (ASCO) spokesman Nicholas J. Vogelzang, MD, head of developmental therapeutics at U.S. Oncology in Las Vegas.

    "These are impressive results. Advances in cancer are almost always incremental," he tells WebMD.

    Vogelzang moderated a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, sponsored by ASCO and two other major cancer groups.

    Cabazitaxel for Prostate Cancer: How It Works

    About 192,000 men were diagnosed with prostate cancer in 2009 and 27,360 men died of the disease, according to Sartor.

    Cabazitaxel is a chemically modified form of the chemotherapy drug Taxotere. That's the drug of last resort for the 15,000 to 20,000 men with advanced prostate cancer that continues to spread despite treatment to reduce the production of the hormone testosterone that fuels prostate cancer cell growth.

    But Taxotere also eventually stops working because prostate cancer cells pump the drug out before it can exert its effects, Sartor says.

    The pump appears to be unable to recognize cabazitaxel, enabling the drug to enter and effectively kill the prostate cancer cells, he says.

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
    cancer fighting foods
    15 Cancer Symptoms Men Ignore
    Prostate Enlarged
    Picture Of The Prostate
    Prostate Cancer Quiz
    screening tests for men
    Prostate Cancer Symptoms
    Vitamin D